Does the media favor PALI or PCRX?

In the previous week, Pacira BioSciences had 42 more articles in the media than Palisade Bio. MarketBeat recorded 52 mentions for Pacira BioSciences and 10 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.80 beat Pacira BioSciences' score of 0.18 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 8 Very Positive mention(s) 11 Positive mention(s) 19 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or ANRO more profitable?

Palisade Bio's return on equity of -33.47% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Alto Neuroscience N/A -46.46% -39.09%

Does the media prefer PALI or ANRO?

In the previous week, Palisade Bio had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 10 mentions for Palisade Bio and 1 mentions for Alto Neuroscience. Palisade Bio's average media sentiment score of 0.80 beat Alto Neuroscience's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SPTX or PALI more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Seaport Therapeutics N/A N/A N/A Palisade Bio N/A -33.47% -31.79%

Does the media prefer SPTX or PALI?

In the previous week, Seaport Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 11 mentions for Seaport Therapeutics and 10 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.80 beat Seaport Therapeutics' score of 0.09 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, HELP or PALI?

Palisade Bio has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Palisade Bio $250K 1,021.22 -$16.78M -$0.48 N/A

Is HELP or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Palisade Bio N/A -33.47% -31.79%

Does the media favor HELP or PALI?

In the previous week, Palisade Bio had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for Palisade Bio and 6 mentions for Cybin. Palisade Bio's average media sentiment score of 0.80 beat Cybin's score of 0.71 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palisade Bio (PALI) Competitors

$1.44 -0.02 (-1.37%)

As of 09:57 AM Eastern

Compare

PALI vs. PCRX, ANRO, SPTX, TBPH, and HELP

Should you buy Palisade Bio stock or one of its competitors? Palisade Bio's main competitors and comparable companies include Pacira BioSciences (PCRX), Alto Neuroscience (ANRO), Seaport Therapeutics (SPTX), Theravance Biopharma (TBPH), and Cybin (HELP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Palisade Bio compare to Pacira BioSciences?

Palisade Bio (NASDAQ:PALI) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Pacira BioSciences has a net margin of 1.96% compared to Palisade Bio's net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Pacira BioSciences	1.96%	9.68%	5.30%

Palisade Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,021.22	-$16.78M	-$0.48	N/A
Pacira BioSciences	$726.41M	1.99	$7.03M	$0.35	103.74

Palisade Bio currently has a consensus price target of $9.29, indicating a potential upside of 533.84%. Pacira BioSciences has a consensus price target of $33.33, indicating a potential downside of 8.20%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Palisade Bio is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pacira BioSciences	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pacira BioSciences had 42 more articles in the media than Palisade Bio. MarketBeat recorded 52 mentions for Pacira BioSciences and 10 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.80 beat Pacira BioSciences' score of 0.18 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	8 Very Positive mention(s)	11 Positive mention(s)	19 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pacira BioSciences beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Alto Neuroscience?

Palisade Bio (NASDAQ:PALI) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, Palisade Bio had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 10 mentions for Palisade Bio and 1 mentions for Alto Neuroscience. Palisade Bio's average media sentiment score of 0.80 beat Alto Neuroscience's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio presently has a consensus target price of $9.29, indicating a potential upside of 533.84%. Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 68.32%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Palisade Bio's return on equity of -33.47% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Alto Neuroscience	N/A	-46.46%	-39.09%

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palisade Bio has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,021.22	-$16.78M	-$0.48	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Palisade Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

Palisade Bio beats Alto Neuroscience on 12 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Seaport Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 11 mentions for Seaport Therapeutics and 10 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.80 beat Seaport Therapeutics' score of 0.09 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Palisade Bio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than Seaport Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Palisade Bio	$250K	1,021.22	-$16.78M	-$0.48	N/A

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Palisade Bio	N/A	-33.47%	-31.79%

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Seaport Therapeutics presently has a consensus target price of $38.57, suggesting a potential upside of 139.87%. Palisade Bio has a consensus target price of $9.29, suggesting a potential upside of 533.84%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Palisade Bio beats Seaport Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Theravance Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86
Palisade Bio	$250K	1,021.22	-$16.78M	-$0.48	N/A

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Palisade Bio had 10 more articles in the media than Theravance Biopharma. MarketBeat recorded 10 mentions for Palisade Bio and 0 mentions for Theravance Biopharma. Palisade Bio's average media sentiment score of 0.80 beat Theravance Biopharma's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Palisade Bio	Positive

Theravance Biopharma currently has a consensus target price of $19.40, suggesting a potential upside of 13.92%. Palisade Bio has a consensus target price of $9.29, suggesting a potential upside of 533.84%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Theravance Biopharma has a net margin of 51.58% compared to Palisade Bio's net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Palisade Bio	N/A	-33.47%	-31.79%

Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Summary

Theravance Biopharma beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Cybin?

Cybin (NASDAQ:HELP) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Cybin has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Cybin presently has a consensus target price of $46.33, indicating a potential upside of 341.27%. Palisade Bio has a consensus target price of $9.29, indicating a potential upside of 533.84%. Given Palisade Bio's higher possible upside, analysts clearly believe Palisade Bio is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

17.9% of Cybin shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Palisade Bio had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for Palisade Bio and 6 mentions for Cybin. Palisade Bio's average media sentiment score of 0.80 beat Cybin's score of 0.71 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Palisade Bio	$250K	1,021.22	-$16.78M	-$0.48	N/A

Palisade Bio's return on equity of -33.47% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Palisade Bio	N/A	-33.47%	-31.79%

Summary

Palisade Bio beats Cybin on 11 of the 13 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$250.08M	$12.37B	$7.26B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-2.99	658.01	206.66	19.94
Price / Sales	1,007.28	750.45	562.21	81.34
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	1.66	9.19	10.75	6.03
Net Income	-$16.78M	$2.83B	$3.50B	$380.34M
7 Day Performance	-2.36%	-3.42%	-2.91%	-2.34%
1 Month Performance	-29.51%	-7.48%	-7.38%	-5.31%
1 Year Performance	-21.89%	-5.63%	2.96%	-2.94%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	2.3611 of 5 stars	$1.45 -1.4%	$9.29 +542.6%	-20.8%	$250.08M	$250K	N/A	14	Analyst Forecast
PCRX Pacira BioSciences	2.0447 of 5 stars	$24.76 -1.2%	$30.14 +21.7%	+63.1%	$986.98M	$746.16M	70.74	829
ANRO Alto Neuroscience	1.7338 of 5 stars	$23.74 -1.1%	$37.25 +56.9%	+275.5%	$931.45M	N/A	N/A	68
SPTX Seaport Therapeutics	2.7951 of 5 stars	$17.37 -6.1%	$38.57 +122.1%	N/A	$929.82M	N/A	N/A	58	Analyst Forecast
TBPH Theravance Biopharma	1.7032 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. PCRX, ANRO, SPTX, TBPH, and HELP

How does Palisade Bio compare to Pacira BioSciences?

Summary

How does Palisade Bio compare to Alto Neuroscience?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Summary

How does Palisade Bio compare to Theravance Biopharma?

Summary

How does Palisade Bio compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. PCRX, ANRO, SPTX, TBPH, and HELP

How does Palisade Bio compare to Pacira BioSciences?

Is PALI or PCRX more profitable?

Which has more volatility and risk, PALI or PCRX?

Which has stronger valuation & earnings, PALI or PCRX?

Do analysts prefer PALI or PCRX?

Do insiders and institutionals believe in PALI or PCRX?

Does the media favor PALI or PCRX?

Summary

How does Palisade Bio compare to Alto Neuroscience?

Does the media prefer PALI or ANRO?

Do analysts recommend PALI or ANRO?

Is PALI or ANRO more profitable?

Do institutionals & insiders have more ownership in PALI or ANRO?

Which has stronger valuation & earnings, PALI or ANRO?

Which has more risk and volatility, PALI or ANRO?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Does the media prefer SPTX or PALI?

Which has higher valuation & earnings, SPTX or PALI?

Is SPTX or PALI more profitable?

Do insiders & institutionals have more ownership in SPTX or PALI?

Do analysts prefer SPTX or PALI?

Summary

How does Palisade Bio compare to Theravance Biopharma?

Which has preferable earnings and valuation, TBPH or PALI?

Do insiders and institutionals have more ownership in TBPH or PALI?

Does the media favor TBPH or PALI?

Do analysts prefer TBPH or PALI?

Is TBPH or PALI more profitable?

Which has more volatility and risk, TBPH or PALI?

Summary

How does Palisade Bio compare to Cybin?

Which has more risk and volatility, HELP or PALI?

Do analysts recommend HELP or PALI?

Do institutionals & insiders believe in HELP or PALI?

Does the media favor HELP or PALI?

Which has preferable earnings and valuation, HELP or PALI?

Is HELP or PALI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools